arGEN-X completes first dosing of ARGX-113 for severe autoimmune disorders
22 October 2015, Breda, The Netherlands / Ghent, Belgium – arGEN-X N.V. (Euronext Brussels: ARGX) today announces the completion of the first human dosing of ARGX-113, a potential breakthrough therapy for the treatment of autoimmune crisis.
“The first dosing of healthy volunteers in our Phase 1 study marks an important step forward for ARGX-113. ARGX-113 has a completely novel approach to managing acute crises related to a large number of IgG-mediated autoimmune diseases such as systemic lupus erythematosus as well as a wide range of serious autoimmune orphan diseases for which there are currently insufficient treatment options,” comments Tim Van Hauwermeiren, CEO of arGEN-X. “ARGX-113 demonstrated high potency and rapid onset of action in a preclinical setting and has an exciting potential to treat patients in high unmet medical need.”
The Phase 1 study is a double-blinded and placebo-controlled study in healthy volunteers. The objective is to evaluate the safety and tolerability profile of ARGX-113 and to identify a potential dose for future Phase 2/3 studies. Topline results from the Phase 1 study are expected in the first half of 2016.